These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

528 related items for PubMed ID: 26518328

  • 1. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
    Cao C, Kuang M, Xu W, Zhang X, Chen J, Tang C.
    Jpn J Clin Oncol; 2015 Dec; 45(12):1122-30. PubMed ID: 26518328
    [Abstract] [Full Text] [Related]

  • 2. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
    Li Y, Sun J, Jiang Z, Zhang L, Liu G.
    J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
    [Abstract] [Full Text] [Related]

  • 3. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O, Elsayed Z, Elhalawani H.
    Cochrane Database Syst Rev; 2018 Apr 06; 4(4):CD011746. PubMed ID: 29624208
    [Abstract] [Full Text] [Related]

  • 4. TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
    Ioka T, Ueno M, Ueno H, Park JO, Chang HM, Sasahira N, Kanai M, Chung IJ, Ikeda M, Nakamori S, Mizuno N, Omuro Y, Yamaguchi T, Hara H, Sugimori K, Furuse J, Maguchi H, Furukawa M, Fukuzawa K, Kim JS, Yukisawa S, Takeuchi M, Okusaka T, Boku N, Hyodo I.
    Eur J Cancer; 2019 Jan 06; 106():78-88. PubMed ID: 30471651
    [Abstract] [Full Text] [Related]

  • 5. A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer.
    Saito K, Isayama H, Nakai Y, Takahara N, Ishigaki K, Takeda T, Hakuta R, Saito T, Uchino R, Kishikawa T, Hamada T, Mizuno S, Sasaki T, Kogure H, Matsubara S, Yamamoto N, Ijichi H, Tateishi K, Tada M, Koike K.
    Invest New Drugs; 2019 Apr 06; 37(2):338-344. PubMed ID: 30411217
    [Abstract] [Full Text] [Related]

  • 6. A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
    Oh DY, Cha Y, Choi IS, Yoon SY, Choi IK, Kim JH, Oh SC, Kim CD, Kim JS, Bang YJ, Kim YH.
    Cancer Chemother Pharmacol; 2010 Feb 06; 65(3):527-36. PubMed ID: 19578850
    [Abstract] [Full Text] [Related]

  • 7. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
    Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M.
    J Clin Oncol; 2013 May 01; 31(13):1640-8. PubMed ID: 23547081
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.
    Hamada C, Okusaka T, Ikari T, Isayama H, Furuse J, Ishii H, Nakai Y, Imai S, Okamura S.
    Br J Cancer; 2017 Jun 06; 116(12):1544-1550. PubMed ID: 28472821
    [Abstract] [Full Text] [Related]

  • 9. Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study.
    Imaoka H, Ikeda M, Maehara K, Umemoto K, Ozaka M, Kobayashi S, Terashima T, Inoue H, Sakaguchi C, Tsuji K, Shioji K, Okamura K, Kawamoto Y, Suzuki R, Shirakawa H, Nagano H, Ueno M, Morizane C, Furuse J.
    BMC Cancer; 2020 Oct 01; 20(1):946. PubMed ID: 33004032
    [Abstract] [Full Text] [Related]

  • 10. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer.
    Okusaka T, Miyakawa H, Fujii H, Nakamori S, Satoh T, Hamamoto Y, Ito T, Maguchi H, Matsumoto S, Ueno H, Ioka T, Boku N, Egawa S, Hatori T, Furuse J, Mizumoto K, Ohkawa S, Yamaguchi T, Yamao K, Funakoshi A, Chen JS, Cheng AL, Sato A, Ohashi Y, Tanaka M, GEST group.
    J Cancer Res Clin Oncol; 2017 Jun 01; 143(6):1053-1059. PubMed ID: 28210843
    [Abstract] [Full Text] [Related]

  • 11. Gemcitabine plus S-1 for metastatic pancreatic cancer.
    Zhu H, Yi C, Zhao Y, Gou H.
    Medicine (Baltimore); 2018 Oct 01; 97(41):e12836. PubMed ID: 30313120
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Biweekly gemcitabine plus S-1 for locally advanced and metastatic pancreatic cancer: a preliminary feasibility study.
    Wada K, Sano K, Amano H, Miura F, Toyota N, Ito H, Shibuya M, Ikeda Y, Kainuma M, Takada T.
    J Hepatobiliary Pancreat Sci; 2015 Sep 01; 22(9):692-8. PubMed ID: 26136371
    [Abstract] [Full Text] [Related]

  • 14. Clinical outcome of gemcitabine/S-1 combination therapy for advanced pancreatic cancer.
    Yamauchi J, Kanai M, Matsumoto S, Nishimura T, Yazumi S, Kami K, Kawaguchi Y, Yasuda H, Kitano T, Misawa A, Ishiguro H, Yoshikawa K, Yanagihara K, Fukushima M, Doi R, Chiba T.
    Pancreas; 2008 Apr 01; 36(3):327-8. PubMed ID: 18362852
    [No Abstract] [Full Text] [Related]

  • 15. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
    Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson AB.
    J Clin Oncol; 2009 Aug 10; 27(23):3778-85. PubMed ID: 19581537
    [Abstract] [Full Text] [Related]

  • 16. Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805).
    Takashima A, Morizane C, Ishii H, Nakamura K, Fukuda H, Okusaka T, Furuse J.
    Jpn J Clin Oncol; 2010 Dec 10; 40(12):1189-91. PubMed ID: 20630899
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: combined meta-analysis of efficacy and safety profile.
    Liu Y, Huang QK, Hong WD, Wu JM, Sun XC.
    Clin Res Hepatol Gastroenterol; 2015 Apr 10; 39(2):254-60. PubMed ID: 25304193
    [Abstract] [Full Text] [Related]

  • 19. Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study.
    Imaoka H, Kou T, Tanaka M, Egawa S, Mizuno N, Hijioka S, Hara K, Yazumi S, Shimizu Y, Yamao K.
    Eur J Cancer; 2016 Feb 10; 54():96-103. PubMed ID: 26741729
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.